CCO Management Series

Choosing First-Line Therapy in Chronic Hepatitis B

Module

Management of Hepatitis B: Understanding Treatment Candidacy and Factors for Selecting Initial Therapy

Faculty:

Kris V. Kowdley, MD, FACP
  • Kris V. Kowdley, MD, FACP

CME CREDIT INFORMATION

Release Date: 07/12/07

Expiration Date: 07/11/08


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status
Begin the Module

Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the goals of hepatitis B virus (HBV) therapy in hepatitis B e antigen (HBeAg)–negative and HBeAg-positive hepatitis B patients
  • Summarize the efficacy data for currently available HBV therapies
  • Discuss the factors for selecting optimal first-line therapy in hepatitis B patients

Interactive Case Challenges

Treatment of an HBeAg-Negative 47-Year-Old Man Presenting Following Routine Screening for Hepatitis B

Faculty:

Robert G. Gish, MD
  • Robert G. Gish, MD

CME CREDIT INFORMATION

Release Date: 06/26/07

Expiration Date: 06/25/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Case Challenge

Test your ability to manage frontline treatment of an asymptomatic 47-year-old Asian male with chronic hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recall guidelines for determining treatment candidacy in treatment-naive patients with HBeAg-negative chronic hepatitis B
  • Describe factors involved in selecting first-line therapy for hepatitis B
  • Discuss management of virologic resistance in patients with chronic hepatitis B

Management of a 38-Year-Old HBeAg-Positive Asian American Man Seeking First-Line Treatment for Hepatitis B

Faculty:

Norah Terrault, MD, MPH
  • Norah Terrault, MD, MPH

CME CREDIT INFORMATION

Release Date: 05/25/07

Expiration Date: 05/24/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Case Challenge

Norah Terrault, MD, MPH, describes the factors underlying first-line treatment decisions in HBeAg-positive patients with chronic hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe criteria for selecting optimal first-line therapy in HBeAg-positive patients
  • Discuss strategies for managing resistance in HBeAg-positive patients
  • Recount data regarding the optimal duration of treatment and posttreatment monitoring strategies in HBeAg-positive patients

Virtual Presentation

Choosing First-Line Therapy in Chronic Hepatitis B

Faculty:

Emmet B. Keeffe, MD, MACP
  • Emmet B. Keeffe, MD, MACP

CME CREDIT INFORMATION

Release Date: 07/05/07

Expiration Date: 07/04/08


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status
Begin the Virtual Presentation

Emmet B. Keeffe, MD, MACP, discusses factors involved in selecting first-line therapy for chronic hepatitis B by reviewing 3 typical patient cases.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recount clinical data on available therapies for the treatment of chronic hepatitis B
  • Describe the key factors used in making decisions regarding first-line treatment in patients with chronic hepatitis B
  • Discuss the clinical situations in which each available HBV therapy would be the most appropriate choice for first-line treatment

Choosing First-Line Therapy in Chronic Hepatitis B


Format: Microsoft PowerPoint (.ppt) | File size: 582 KB


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.